The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical impact of the rapid genomic screening platform for non-small cell lung cancer in Asia-Pacific (LC-SCRUM-AP).
 
Shigeki Umemura
Honoraria - Chugai Pharma
 
Chih-Hsi Kuo
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Guardant Health AMEA; Janssen Oncology; Lilly; Merck; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Guardant Health AMEA; Lilly; Merck; Novartis; Takeda
 
Virote Sriuranpong
Honoraria - Amgen; AstraZeneca; Eisai; MSD Oncology; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; MSD Oncology; Novartis; Roche
Research Funding - Amgen (Inst); AstraZeneca (Inst); MSD Oncology (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Eisai; Roche
 
Muthukkumaran Thiagarajan
No Relationships to Disclose
 
Charuwan Akewanlop
Speakers' Bureau - Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca/MedImmune; Roche
 
Yuri Murata
No Relationships to Disclose
 
Yuji Shibata
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Blueprint Medicines (Inst); Chugai Pharma (Inst); MSD (Inst); Novartis (Inst)
 
Methaneethorn Prae
Employment - Precision Medicine Asia
 
Tatsuya Ikeda
Employment - Precision Medicine Asia
 
Kaori Egami
Employment - Precision Medicine Asia
 
Genevieve Chase
Employment - PREMIA Holdings (HK) Limited
Consulting or Advisory Role - Amoy Diagnostics
 
Christer Svedman
Employment - Npowermedicine Inc
Leadership - Npowermedicine Inc
Stock and Other Ownership Interests - Alnylam; Cantargia AB; Crispr Therapeutics; Moderna Therapeutics; Neurocrine Biosciences; Npowermedicine Inc; TP Therapeutics; Vertex
Consulting or Advisory Role - PREMIA
Patents, Royalties, Other Intellectual Property - Patents on gene expression algorithm (Genomic Health)
 
Takashi Seto
Employment - Precision Medicine Asia
Honoraria - Amgen; Anheart Therapeutics; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; GlaxoSmithKline; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Pfizer; Takeda
 
Hiroki Izumi
Honoraria - Bristol-Myers Squibb Japan; Chugai/Roche; Lilly; Merck; MSD; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen
Research Funding - Abbvie (Inst); Amgen (Inst); ArriVent Biopharma (Inst); AstraZeneca (Inst); Eisai/MSD (Inst); Ono Pharmaceutical (Inst); Takeda (Inst)
 
Shingo Matsumoto
Honoraria - Amgen; AstraZeneca; Chugai Pharma; Guardant Health; Lilly; Merck; Novartis; Riken; Thermo Fisher Scientific
Consulting or Advisory Role - Janssen
Research Funding - Chugai Pharma (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst)
 
Koichi Goto
Honoraria - Amgen; Amoy Diagnostics; AstraZeneca Japan; Bristol-Myers Squibb K.K.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health; iTeos Therapeutics Inc.; Janssen; Lilly Japan; Merck; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pharma Mar, S.A.; RIKEN GENESIS CO., LTD.; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - Amgen; Amgen; AstraZeneca Japan; Bayer; Bristol-Myers Squibb K.K.; DAIICHI SANKYO Co., Ltd.; GlaxoSmithKline K.K.; Haihe Biopharma Co., Ltd.; Janssen; Lilly Japan; Syneos Health
Research Funding - Abbvie (Inst); Amgen (Inst); Amgen (Inst); AnHeart Therapeutics Inc. (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb K.K. (Inst); Chugai Pharma (Inst); CRAIF Inc. (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Eisai (Inst); Guardant Health Asia, Middle East & Africa, Inc (Inst); HaiHe Biopharma Co., Ltd. (Inst); Ignyta (Inst); Janssen (Inst); Kyowa Kirin Co., Ltd. (Inst); Life Technologies (Inst); Lilly Japan (Inst); Loxo (Inst); Lunit (Inst); MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (Inst); Merck (Inst); Merus (Inst); MSD K.K. (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Precision Medicine Asia Co., Ltd. (Inst); RIKEN GENESIS CO., LTD. (Inst); Spectrum Pharmaceuticals (Inst); Sumitomo Pharma Co., Ltd. (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Turning Point Therapeutics (Inst)